Chronic l-dopa administration is associated with development of dyskinesias. The molecular mechanisms of these side-effects, however, remain elusive. Dopamine (DA) receptors interact with other receptors to form highly organized complexes where their activity is finely tuned by several proteins. The DA D1R forms a heteromeric complex with the NMDA receptor (NMDAR) and this interaction influences the trafficking of both receptors. Using the 6-hydroxydopamine rat model of Parkinson's disease, we report a correlation between the development of l-dopa-induced dyskinesias and changes in synaptic D1R/NMDAR complexe
Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associate...
Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associate...
International audienceDyskinesia is a major side effect of chronic levodopa (L-DOPA) administration,...
Glutamate-mediated mechanisms are related to the motor complications of L-DOPA therapy in Parkinson’...
NTRODUCTION: Several types of D2R and D1R heteroreceptor complexes were discovered in the indirect ...
Lu Song,1,* Zhanzhao Zhang,2,* Rongguo Hu,1 Jie Cheng,1 Lin Li,1 Qinyi Fan,1 Na Wu,1 Jing Gan,1 Ming...
Parkinson?s Disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminer...
Abnormal function of NMDA receptor has been suggested to be correlated with the pathogenesis of Park...
Levodopa (L-DOPA)-induced dyskinesias represent the main side effect of the therapeutic strategy cli...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
Na Wu, Ying Wan, Lu Song, Chen Qi, Zhenguo Liu, Jing Gan Department of Neurology, Xinhua Hospital, ...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
The dopamine (DA) precursor L-DOPA remains the most common treatment for Parkinson's disease (PD). H...
Metabotropic glutamate receptor type 5 (mGluR5) modulates dopamine and glutamate neurotransmission a...
Parkinson's disease and L-DOPA-induced dyskinesia (LID) does not merely involve the dopamine (DA) sy...
Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associate...
Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associate...
International audienceDyskinesia is a major side effect of chronic levodopa (L-DOPA) administration,...
Glutamate-mediated mechanisms are related to the motor complications of L-DOPA therapy in Parkinson’...
NTRODUCTION: Several types of D2R and D1R heteroreceptor complexes were discovered in the indirect ...
Lu Song,1,* Zhanzhao Zhang,2,* Rongguo Hu,1 Jie Cheng,1 Lin Li,1 Qinyi Fan,1 Na Wu,1 Jing Gan,1 Ming...
Parkinson?s Disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminer...
Abnormal function of NMDA receptor has been suggested to be correlated with the pathogenesis of Park...
Levodopa (L-DOPA)-induced dyskinesias represent the main side effect of the therapeutic strategy cli...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
Na Wu, Ying Wan, Lu Song, Chen Qi, Zhenguo Liu, Jing Gan Department of Neurology, Xinhua Hospital, ...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
The dopamine (DA) precursor L-DOPA remains the most common treatment for Parkinson's disease (PD). H...
Metabotropic glutamate receptor type 5 (mGluR5) modulates dopamine and glutamate neurotransmission a...
Parkinson's disease and L-DOPA-induced dyskinesia (LID) does not merely involve the dopamine (DA) sy...
Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associate...
Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associate...
International audienceDyskinesia is a major side effect of chronic levodopa (L-DOPA) administration,...